Heparin

Evidence Level: L5

Predicted Indications: 2

Heparin

Pharmacist Assessment Report

Heparin: From Pulmonary Embolism to Thrombophilia due to Protein C Deficiency, Autosomal Recessive

One-Sentence Summary

Heparin is an anticoagulant originally used for pulmonary embolism, disseminated intravascular coagulation and purpura fulminans. The TxGNN model predicts it may be useful for thrombophilia due to protein C deficiency, autosomal recessive, but no clinical trials and no publications specific to this indication were found, so the support is model prediction only.

Quick Overview

Item	Content
Original Indication	Pulmonary embolism, disseminated intravascular coagulation, purpura fulminans, acquired purpura fulminans
Predicted New Indication	Thrombophilia due to protein C deficiency, autosomal recessive
TxGNN Prediction Score	0.9929
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, heparin enhances antithrombin activity and thereby inhibits thrombin and factor Xa. This can offset the hypercoagulable state seen when protein C, a natural anticoagulant, is deficient.

The new indication is closely linked to one of heparin’s existing indications. Purpura fulminans is a severe manifestation of homozygous or compound heterozygous protein C deficiency. The high TxGNN score is probably driven largely by this overlap and is a computational prediction only.

In practice, this condition is managed mainly with protein C concentrate and other anticoagulation, with heparin as an adjunct. This comes from general knowledge and is not supported by the data compiled for this report.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for this indication.

India Market Information

Approved indication text is not available for any of the registrations. The 20 valid single-ingredient registrations include injectable vials (1 ml, 5 ml and 10 ml presentations) and one topical ointment. Main examples:

Authorization Number	Product Name	Dosage Form	Approved Indication
105298	Heprin 5000IU Injection	Vial of 1 injection	Not specified
103797	Heparin Sodium 5000IU Injection	Vial of 5 ml injection	Not specified
104120	Heparin 25000IU Injection	Vial of 5 ml injection	Not specified
103909	Hep Lock Solution	Vial of 10 ml injection	Not specified
104449	Hepgel 250IU Ointment	Tube of 15 g ointment	Not specified

Safety Considerations

Contraindications (from knowledge-graph drug-disease links, not label text): liver failure, thrombocytopenia, heparin-induced thrombocytopenia, blood coagulation disease, hemophilia, antithrombin III deficiency, Glanzmann thrombasthenia and qualitative platelet defects, intracranial and intracerebral hemorrhage, placental abruption, active peptic ulcer disease, ulcerative colitis and inflammatory bowel disease, infective endocarditis, retinal diseases (including diabetic and hypertensive retinopathy), biliary tract disease, obstructive jaundice, osteoporosis.
Drug Interactions: 614 interactions were identified. Moderate-level interactions include acetylsalicylic acid and several antidiabetic agents (chlorpropamide, glimepiride, glipizide, glyburide, tolbutamide, tolazamide, acetohexamide, repaglinide, nateglinide), as well as fenfluramine, dexfenfluramine and sibutramine.

Please also refer to the package insert for label-based warnings and contraindications, which were not available for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is biologically plausible and fits with heparin’s existing use in purpura fulminans. However, there are no trials or publications for this indication, and the evidence is model prediction only (L5). Label-based safety information is also missing.

To proceed, the following is needed:

Targeted literature review of heparin use in severe congenital protein C deficiency and purpura fulminans, including comparison with protein C concentrate
Mechanism of action data from DrugBank
Package insert warnings and contraindications from the India registrations
Confirmation of approved indications on the Indian labels
Clinical expert review of bleeding risk and the role of heparin as an adjunct
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.